• Tetracycline in Senescence Assay Design

  2026-09-08

  Tetracycline is more than a broad-spectrum polyketide antibiotic in experimental workflows: it can shape how researchers interpret selection, translation, and cell-state measurements. This article connects its mechanism to the LKB1–telomerase findings in lung adenocarcinoma while defining practical controls for reproducible senescence assays.

• Comparing SGLT2 Inhibitors in Diabetes and Heart Failure

  2026-09-08

  This systematic review and network meta-analysis compared five SGLT2 inhibitors across 11 randomized trials involving patients with type 2 diabetes and heart failure. Its main contribution is an indirect comparative framework showing consistent reduction in heart-failure hospitalization, while also indicating that individual agents may differ for composite cardiovascular outcomes.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-09-07

  Dimethyloxalylglycine (DMOG), SKU A4506, provides a practical chemical approach for studying hypoxia-inducible factor stabilization and related oxygen-sensing responses under normoxic culture conditions. It is intended for controlled in vitro and selected preclinical research workflows, not for diagnostic, therapeutic, or clinical use.

• Acifran: Practical Workflows for HCAR Signaling

  2026-09-07

  Build more interpretable lipid-receptor experiments with Acifran, from controlled cAMP assays to receptor-comparison studies informed by cryo-EM. This guide combines practical dosing, plate design, troubleshooting, and structure-guided choices for lipid metabolism and metabolic disorder research.

• Amikacin Sulfate Workflows for NTM Delivery

  2026-09-05

  Build a connected workflow for measuring Amikacin activity, intracellular uptake, and granuloma localization in non-tuberculous mycobacterial models. The approach separates free-drug killing from dendritic-cell-mediated targeting, helping researchers interpret CFU, fluorescence, and tissue-distribution results without overstating translational evidence.

• I-BET151 (GSK1210151A): Practical Lab Guide

  2026-09-04

  I-BET151 (GSK1210151A), SKU B1500, provides a controlled way to investigate BRD2, BRD3, and BRD4 bromodomain inhibition in cancer biology workflows, including apoptosis and cell cycle arrest assays. It is a research reagent for in vitro and preclinical laboratory studies, not a diagnostic, clinical, or therapeutic product.

• Acifran: HCAR2/HCAR3 Lipid Signaling Tool

  2026-09-04

  Acifran is a research agonist of HM74A/GPR109A and GPR109B used to investigate lipid signaling pathway modulation. Cryo-EM structures directly place Acifran in HCAR2- and HCAR3-Gi receptor complexes, providing a structural benchmark for lipid metabolism regulation studies.

• H2S Deficiency and ER Stress in Diabetic Cardiomyopathy

  2026-09-03

  The reference study identifies reduced endogenous hydrogen sulfide production as a mechanistic component of lipid-induced myocardial injury in diabetic cardiomyopathy. Using patient samples, diabetic rats, and palmitate-treated cardiomyocytes, it links H2S deficiency with ER-stress-associated apoptosis and shows that H2S donation produces protective effects similar to ER-stress inhibition.

• AO/PI Double Staining Kit: Practical Workflow

  2026-09-03

  The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates green viable cells, orange apoptotic cells, and red PI-positive cells in one preparation. It is suitable for controlled in vitro cell biology workflows, but it should not be treated as a standalone mechanistic assay or an in vivo test.

• Methicillin Resistance: MRSA Research and Clinical Insights

  2026-09-02

  Turner and colleagues provide an integrative review of how mecA, SCCmec, strain evolution, transmission, and clinical management shape methicillin-resistant Staphylococcus aureus (MRSA) disease. The review’s practical value lies in connecting molecular resistance biology with epidemiology and treatment decisions, while clarifying why colonization, infection, and source control must be studied together.

• Sulfasalazine for Sarcopenia: Study Insights

  2026-09-02

  The reference study identifies sulfasalazine through a PHF20–YY1 transcriptional assay and links reduced YY1 activity with improved myogenic phenotypes, muscle performance, and muscle preservation in experimental and clinical datasets. Its findings support a drug-repurposing hypothesis for sarcopenia, particularly in inflammatory bowel disease, while remaining preliminary because the clinical evidence is associative and the effective cellular concentration requires further translational evaluation.

• Lopinavir A8204 for Reliable Cell Assays

  2026-09-01

  Learn how Lopinavir (ABT-378, SKU A8204) can support reproducible HIV protease inhibition, cell viability, and antiviral assay workflows. This scenario-based guide covers solvent handling, concentration selection, cytotoxicity controls, cross-pathogen interpretation, and practical product evaluation.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-09-01

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat-derived IgG primary antibodies in ICC/IF, IHC, flow cytometry, and ELISA workflows. It should not be used as a direct antigen-detection reagent or with non-goat primary antibodies, and assay-specific dilution and imaging conditions require optimization.

• Hesperadin: Aurora B Kinase Inhibitor Workflows

  2026-08-31

  Hesperadin provides a practical way to connect Aurora B activity with histone H3 phosphorylation, chromosome segregation, cytokinesis, and polyploidization. This workflow-focused guide shows how to use it alongside checkpoint assays while distinguishing Aurora B perturbation from the Plk1–p31comet mechanism described in the reference study.

• Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells

  2026-08-31

  Kartal and colleagues developed a phenotypic screening and delivery strategy to reduce SPP1 expression in tumor-associated macrophages. The lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, supporting TAM reprogramming as a therapeutic research direction.

8349 records 1/557 page Next 12345 下5页 Last page